Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.
This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of AIHA’s have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for AIHA include:
• Lymphoproliferative conditions:
o CLL
o HL
o NHL
• Myeloproliferative conditions:
o Multiple myeloma
o Myelofibrosis
o MGUS
• Autoimmune conditions:
o RA
o SLE
o Polyarteritis nodosa
• Infections:
o Pneumonia & Tuberculosis
o Syphilis
o Epstein-Barr
o Chronic active hepatitis
o Mononucleosis
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global AIHA’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on AIHA’s incident population.
• Identify sub-populations within AIHA which require treatment.
• Gain an understanding of the specific markets that have the largest number of AIHA patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Clinical Management of AIHA
o Transfusion therapy in AIHA
• Key Co-morbid Conditions/Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Incidence for AIHA
• Subtypes of AIHA patients
o Warm AIHA patients
o Cold AIHA patients
o Mixed-type AIHA patients
• Market Forecast for AIHA
o 1st Line Treatment Options within Warm & Mixed-type AIHA
o 2nd Line Treatment Options within Warm & Mixed-type AIHA
o 1st Line Treatment Options within Cold AIHA
o 2nd Line Treatment Options within Cold AIHA
o Requirement for Blood Transfusions within AIHA
• Methodology for Forecast Figures
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Drugs implicated in development of AIHA
• Tests for AIHA and expected findings in haemolysis
• Classification of AIHA
• Treatment options for warm AIHA
• Treatment options for cold AIHA
• Incidence of AIHA, total (000s)
• Incidence of AIHA, males (000s)
• Incidence of AIHA, females (000s)
• Incident AIHA by main sub-type, total (000s)
• Incident Warm AIHA by cause, total (000s)
• Warm Secondary AIHA by main aetiology, total (000s)
• Incident Cold AIHA by main type, total (000s)
• Incident CAS AIHA by cause, total (000s)
• CAS Secondary AIHA by main aetiology, total (000s)
• Incident Mixed-type AIHA by cause, total (000s)
• Mixed-type Secondary AIHA by main aetiology, total (000s)
• Prednisolone estimated forecast 1st line, Revenue (£000s)
• Rituximab estimated forecast 2nd line, Revenue (£000s)
• Splenectomy estimated forecast 2nd line, Patients (000s)
• Rituximab estimated forecast 1st line, Revenue (£000s)
• Rituximab estimated forecast 2nd line, Revenue (£000s)
• Transfusion estimated forecast, Patients (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of AIHA by 5-yr age cohort, males (000s)
• USA Incidence of AIHA by 5-yr age cohort, females (000s)
• France Incidence of AIHA by 5-yr age cohort, males (000s)
• France Incidence of AIHA by 5-yr age cohort, females (000s)
• Germany Incidence of AIHA by 5-yr age cohort, males (000s)
• Germany Incidence of AIHA by 5-yr age cohort, females (000s)
• Italy Incidence of AIHA by 5-yr age cohort, males (000s)
• Italy Incidence of AIHA by 5-yr age cohort, females (000s)
• Spain Incidence of AIHA by 5-yr age cohort, males (000s)
• Spain Incidence of AIHA by 5-yr age cohort, females (000s)
• UK Incidence of AIHA by 5-yr age cohort, males (000s)
• UK Incidence of AIHA by 5-yr age cohort, females (000s)
• Brazil Incidence of AIHA by 5-yr age cohort, males (000s)
• Brazil Incidence of AIHA by 5-yr age cohort, females (000s)
• Japan Incidence of AIHA by 5-yr age cohort, males (000s)
• Japan Incidence of AIHA by 5-yr age cohort, females (000s)
